GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NovaBay Pharmaceuticals Inc (AMEX:NBY) » Definitions » Cyclically Adjusted FCF per Share

NovaBay Pharmaceuticals (NovaBay Pharmaceuticals) Cyclically Adjusted FCF per Share : $-2,414.04 (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is NovaBay Pharmaceuticals Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

NovaBay Pharmaceuticals's adjusted free cash flow per share for the three months ended in Mar. 2024 was $-2.233. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-2,414.04 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 16.40% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 7.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of NovaBay Pharmaceuticals was 17.80% per year. The lowest was -1.00% per year. And the median was 12.00% per year.

As of today (2024-06-09), NovaBay Pharmaceuticals's current stock price is $2.71. NovaBay Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $-2,414.04. NovaBay Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


NovaBay Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

The historical data trend for NovaBay Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovaBay Pharmaceuticals Cyclically Adjusted FCF per Share Chart

NovaBay Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4,742.82 -5,040.98 -5,018.58 -4,513.30 -2,945.48

NovaBay Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4,112.09 -3,869.35 -3,586.69 -2,945.48 -2,414.04

Competitive Comparison of NovaBay Pharmaceuticals's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, NovaBay Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NovaBay Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NovaBay Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where NovaBay Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



NovaBay Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, NovaBay Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-2.233/131.7762*131.7762
=-2.233

Current CPI (Mar. 2024) = 131.7762.

NovaBay Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -1,881.000 100.560 -2,464.919
201409 -1,394.000 100.428 -1,829.135
201412 -2,072.500 99.070 -2,756.707
201503 -2,260.500 99.621 -2,990.131
201506 -2,716.500 100.684 -3,555.385
201509 -2,081.000 100.392 -2,731.569
201512 -1,522.000 99.792 -2,009.806
201603 -1,649.667 100.470 -2,163.690
201606 -446.833 101.688 -579.045
201609 -432.111 101.861 -559.016
201612 -25.167 101.863 -32.558
201703 -172.083 102.862 -220.455
201706 -142.917 103.349 -182.228
201709 16.000 104.136 20.247
201712 -226.308 104.011 -286.719
201803 -33.286 105.290 -41.659
201806 -106.857 106.317 -132.446
201809 -116.143 106.507 -143.699
201812 -144.571 105.998 -179.730
201903 -231.071 107.251 -283.912
201906 -118.933 108.070 -145.023
201909 -78.947 108.329 -96.034
201912 -62.130 108.420 -75.514
202003 -37.609 108.902 -45.509
202006 -41.640 108.767 -50.449
202009 -41.515 109.815 -49.817
202012 -41.286 109.897 -49.506
202103 -42.471 111.754 -50.080
202106 -56.829 114.631 -65.329
202109 -40.135 115.734 -45.698
202112 -116.919 117.630 -130.980
202203 -50.756 121.301 -55.139
202206 -39.698 125.017 -41.844
202209 -38.457 125.227 -40.468
202212 -22.389 125.222 -23.561
202303 -20.690 127.348 -21.409
202306 -24.934 128.729 -25.524
202309 -2.724 129.860 -2.764
202312 -0.984 129.419 -1.002
202403 -2.233 131.776 -2.233

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


NovaBay Pharmaceuticals  (AMEX:NBY) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


NovaBay Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of NovaBay Pharmaceuticals's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


NovaBay Pharmaceuticals (NovaBay Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
2000 Powell Street, Suite 1150, Emeryville, CA, USA, 94608
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare and skincare products. Its leading product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is proven in laboratory testing to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available direct to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
Executives
Tommy Law officer: Interim CFO 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Jeffrey Kunin officer: President, DERMAdoctor, LLC 4346 BELGIUM BLVD NW, RIVERSIDE MO 64150
Audrey Kunin officer: Chief Product Officer 4346 BELGIUM BLVD NW, RIVERSIDE MO 64150
Justin Hall officer: General Counsel 5980 HORTON STREET, SUITE 550, EMERYVILLE CA 94608
Yongxiang Zheng director NO.10, UNIT 1, LIJING VILLA, TIANZHU, SHUNYI DISTRICT, BEIJING F4 101316
Julie Garlikov director 2420 17TH STREET, SUITE 220, DENVER CO 80202
Andrew D. Jones officer: CFO and Treasurer 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Mijia Wu director SUITE 6C, BLDG 3, YOU YOU CENTURY PLAZA, NO 428 YANG GAO SOUTH ROAD, SHANGHAI F4 CHINA
Jian Ping Fu 10 percent owner LEVEL 1, BLDG 1, GREENWOOD BUSINESS PARK, 301 BURWOOD HWY, BURWOOD C3 3125
Wang Xu officer: NEO - Sr Mgr and Controller 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Swan Sit director 95 JACKSON STREET, NEWTON MA 02459
Yenyou Zheng director 1055 WEST HASTINGS STREET, SUITE 1980, VANCOUVER A1 V6E 2E9
Xiaopei Wang director 2/44 FRANKLIN ROAD, DONCASTER EAST C3 3109
Jason Philip Raleigh officer: Interim CFO and Treasurer 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Pioneer Pharma (hong Kong) Co Ltd 10 percent owner FLAT 2605, 26/F TRENDY CENTRE, 682 CASTLE PEAK ROAD, KOWLOON K3 000000